SEC Form 4 · accession 0001144204-15-012883
Celator Pharmaceuticals Inc · CPXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Lawrence David Mayer
Officer — President and Head of Research
Period of report
Feb 25, 2015
Accepted (ET)
Feb 27, 2015 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001327467
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 25, 2015 | A | 7,639 | $0.00 | A | 18,100 | D | |
| Common Stock | holding | — | — | — | 7,468 | I | By spouse | |
| Common Stock | holding | — | — | — | 3,631 | I | By spouse's trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option, Right to BuyF1 | $2.79 | Feb 25, 2015 | A | 80,000 | A | — | Feb 25, 2025 | Common Stock | 80,000 | 80,000 | D |
Explanation of responses
- F1The options vest as follows: (i) 20,000 options vest on February 25, 2016; and (ii) 12 consecutive quarterly installments of 5,000 options vest on the 25th day of each May, August, November and February, beginning May 125, 2016 and continuing through February 25, 2019.